ObsEva News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

01.12.20	ObsEva SA to present at The International Society of Gynecological Endocrinology 19th World Congress – virtual edition, December 2-5, 2020 (GlobeNewswire)
27.11.20	Pre-market Movers In Healthcare Sector: WORX, GNFT, YMAB, VSTM, TYME… (RTTNews)
24.11.20	ObsEva Submits MAA To EMA For YSELTY For Treatment Of Women With Uterine Fibroids (RTTNews)
24.11.20	ObsEva SA Submits Marketing Authorization Application to the European Medicines Agency for YSELTY® (linzagolix) for the Treatment of Women with Uterine Fibroids (GlobeNewswire)
16.11.20	Pre-market Movers In Healthcare Sector: OBSC, CEMI, ABUS, CVAC, ADMP… (RTTNews)
16.11.20	ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor (GlobeNewswire)
13.11.20	ObsEva SA to present at Jefferies Virtual London Healthcare Conference, November 17 – 19, 2020 (GlobeNewswire)
09.11.20	ObsEva appoints Brian O’Callaghan as Chief Executive Officer (GlobeNewswire)
05.11.20	ObsEva Announces Third Quarter 2020 Financial Results and Business Update (GlobeNewswire)
04.11.20	Pre-market Movers In Healthcare Sector: DRAD, SUPN, ARGX, AZN, APVO… (RTTNews)
02.11.20	ObsEva SA hosts live symposium and presents oral communication at the SEUD Online Week November 3 - 6, 2020 (GlobeNewswire)
22.10.20	ObsEva SA Presented Two Late-Breaking Posters at the ASRM 2020 Virtual Scientific Congress October 17-21 (GlobeNewswire)
20.10.20	ObsEva SA Presented Nolasiban Poster at the ASRM 2020 Virtual Scientific Congress October 17-21 (GlobeNewswire)
16.09.20	Pre-market Movers In Healthcare Sector: TLSA, APDN, AVEO, TNXP, ETON… (RTTNews)
08.09.20	ObsEva SA to present at the H.C Wainwright 22nd Annual Global Investment Virtual Conference, September 14-16, 2020 (GlobeNewswire)
04.09.20	Pre-market Movers In Healthcare Sector: SONN, OBSV, OSUR, CVAC, OCGN... (RTTNews)
03.09.20	ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement Priced At-The-Market of Common Shares and 15-Month Purchase Warrants for Potential Additional Gross Proceeds of (GlobeNewswire)
07.08.20	ObsEva SA to present at the Wedbush PacGrow Healthcare Virtual Conference, August 11 – 12, 2020 (GlobeNewswire)
06.08.20	ObsEva Announces Second Quarter 2020 Financial Results and Business Update (GlobeNewswire)
15.07.20	Pre-market Movers In Healthcare Sector: IMMP, ACOR, CLSN, MRNA, ECOR... (RTTNews)
15.07.20	ObsEva SA Awarded Clinical Science Award for Oral Presentation at ESHRE Virtual 36th Annual Meeting, July 2020 (GlobeNewswire)
07.07.20	BLU Plunges On RELIEF Data, FDA Places CLLS' Trial On Hold, IMMU Hits New High, OTIC Music To Ears (RTTNews)
06.07.20	Pre-Market Movers In Healthcare Sector - OBSV, MGTA, ELGX... (RTTNews)
06.07.20	ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids (GlobeNewswire)
03.07.20	ObsEva SA to present at ESHRE Virtual 36th Annual Meeting, July 5-8, 2020 (GlobeNewswire)
01.07.20	ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA (GlobeNewswire)
30.06.20	FDA Snubs HRTX Again, ICPT Disappoints, KNSA Hits Right Notes, Is The Writing On The Wall For VRCA? (RTTNews)
29.06.20	ObsEva SA to Hold Conference Call Monday, July 6 to Discuss Results from Phase 3 PRIMROSE 1 and PRIMROSE 2 Trials Evaluating Linzagolix in Women with Uterine Fibroids (GlobeNewswire)
20.06.20	Data Readouts Due This Month - Do You Have These Pharma Stocks In Your Portfolio? (RTTNews)
09.06.20	ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2020 Annual General Meeting held on June 9, 2020 (GlobeNewswire)
04.06.20	ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis (GlobeNewswire)
29.05.20	ObsEva SA to present at the Jefferies Virtual Healthcare Conference June 3rd, 2020 (GlobeNewswire)
08.05.20	ObsEva Annual General Meeting 2020 (GlobeNewswire)
05.05.20	ObsEva Announces First Quarter 2020 Financial Results and Business Update (GlobeNewswire)
22.04.20	ObsEva Announces Publication of Abstracts from Phase 2b EDELWEISS Trial of Linzagolix in Endometriosis (GlobeNewswire)
14.04.20	ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares (GlobeNewswire)
06.04.20	ObsEva SA Announces New Interim Chief Financial Officer (GlobeNewswire)
27.03.20	ObsEva SA: New Date Announcement for AGM (GlobeNewswire)
23.03.20	ObsEva Provides Update Related to COVID-19 Pandemic (GlobeNewswire)
05.03.20	ObsEva SA Link to Annual Report 2019 (GlobeNewswire)
05.03.20	ObsEva Announces Year End 2019 Financial Results and Business Update (GlobeNewswire)
27.02.20	ObsEva SA to Hold Year End 2019 Financial Results and Business Update Conference Call on March 5, 2020 (GlobeNewswire)
18.02.20	ObsEva SA to present at the SVB LEERINK 9th Annual Global Healthcare Conference February 26th 2020 (GlobeNewswire)
15.01.20	ObsEva to Outline Corporate Plans For 2020 and Beyond at JP Morgan Healthcare Conference in San Francisco (GlobeNewswire)
13.01.20	ObsEva and Yuyuan BioScience Technology Announce Sublicense Agreement to Develop and Commercialize Nolasiban in the People's Republic of China (GlobeNewswire)
07.01.20	ObsEva SA to Participate in in JP Morgan Healthcare Conference January 13-16, 2020 (GlobeNewswire)
09.12.19	Stock To Watch: ObsEva's PRIMROSE 2 Trial Meets Goals (RTTNews)
09.12.19	ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix (GlobeNewswire)
07.12.19	What Awaits Obseva (OBSV) On Monday? (RTTNews)
06.12.19	ObsEva SA to Hold Conference Call to Discuss PRIMROSE 2 Trial Results on December 9, 2019 (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

27.09.24		Gewinne in Zürich: SPI präsentiert sich zum Ende des Freitagshandels fester
27.09.24		SPI aktuell: SPI klettert
24.09.24		Gewinne in Zürich: SPI beendet den Dienstagshandel mit Gewinnen
23.09.24		Gewinne in Zürich: SPI bewegt schlussendlich im Plus
23.09.24		Gute Stimmung in Zürich: SPI notiert im Plus
21.08.24		Anleger in Zürich halten sich zurück: SPI beendet die Sitzung im Minus
15.08.24		Börse Zürich in Grün: SPI legt zum Handelsende zu
15.08.24		Börse Zürich in Grün: SPI in der Gewinnzone

27.09.24

Gewinne in Zürich: SPI präsentiert sich zum Ende des Freitagshandels fester

27.09.24

SPI aktuell: SPI klettert

24.09.24

Gewinne in Zürich: SPI beendet den Dienstagshandel mit Gewinnen

23.09.24

Gewinne in Zürich: SPI bewegt schlussendlich im Plus

23.09.24

Gute Stimmung in Zürich: SPI notiert im Plus

21.08.24

Anleger in Zürich halten sich zurück: SPI beendet die Sitzung im Minus

15.08.24

Börse Zürich in Grün: SPI legt zum Handelsende zu

15.08.24

Börse Zürich in Grün: SPI in der Gewinnzone

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

CieFinRichemont	121.15	2.19 %	K V
Logitech Intl	72.20	1.66 %	K V
Lonza Grp	526.60	1.00 %	K V
Swiss Re	129.35	0.82 %	K V
UBS Group	28.35	0.18 %	K V
Givaudan	3’901.00	-0.81 %	K V
Swiss Life Hldg	725.40	-1.12 %	K V
Holcim	89.78	-1.12 %	K V
Novartis	91.93	-1.87 %	K V
Sonova Hldg	306.20	-1.89 %	K V

Nachrichten zu ObsEva AG

Aktien Top/Flop

ObsEva Peer Group Nachrichten

Meistgelesene Nachrichten